Exelixis Inc (EXEL)vsModerna Inc (MRNA)
EXEL
Exelixis Inc
$56.12
-2.28%
HEALTHCARE · Cap: $14.62B
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Exelixis Inc generates 9% more annual revenue ($2.44B vs $2.23B). EXEL leads profitability with a 35.3% profit margin vs -141.4%. EXEL earns a higher WallStSmart Score of 70/100 (B-).
EXEL
Strong Buy70
out of 100
Grade: B-
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.9%
Fair Value
$164.33
Current Price
$56.12
$108.21 discount
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 47 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 39.5%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Earnings expanding 26.2% YoY
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : EXEL
The strongest argument for EXEL centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 35.3% and operating margin at 39.5%. Revenue growth of 10.6% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : EXEL
The primary concerns for EXEL are PEG Ratio.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
EXEL profiles as a mature stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
EXEL is growing revenue faster at 10.6% — sustainability is the question.
EXEL generates stronger free cash flow (306M), providing more financial flexibility.
Bottom Line
EXEL scores higher overall (70/100 vs 21/100), backed by strong 35.3% margins and 10.6% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Exelixis Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?